Medicamen Biotech has fixed September 19, 2026, as the record date for the payment of the final dividend for the financial year ended March 31, 2026 (FY26). Shareholders whose names appear in the Register of Members or depository records as on this date will be eligible to receive the dividend, subject to its declaration at the ensuing Annual General Meeting.

The Board of Directors has recommended the final dividend, which requires approval from members at the company’s 33rd Annual General Meeting. The intimation was issued in compliance with Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Section 91 of the Companies Act, 2013.

Book Closure Details

To facilitate the AGM and dividend payment process, Medicamen Biotech will close its Register of Members and Share Transfer Books for a period of seven days. The closure applies to equity shares listed on both the BSE and NSE.

The book closure period runs from Sunday, September 20, 2026, to Saturday, September 26, 2026, inclusive of both days. During this period, no transfers or transmissions of shares will be processed.

Regulatory Compliance

The disclosure was submitted to the stock exchanges by Parul Choudhary, Company Secretary, on August 18, 2026. The company emphasized that the dividend entitlement is strictly determined by the record date and is subject to applicable laws and shareholder approval at the AGM.

Medicamen Biotech reported a significant improvement in profitability for the first quarter of FY27, with standalone net profit rising 54% year-on-year to ₹252.69 lakh. Consolidated net profit attributable to controlling interest grew 14% YoY to ₹211.84 lakh. The financial performance was underpinned by top-line growth, as standalone revenue from operations increased 14% to ₹4,385.27 lakh, while consolidated revenue rose 11% to ₹4,789.69 lakh.

The company’s operational efficiency improved alongside revenue growth. Standalone profit before tax (PBT) expanded 50% YoY to ₹325.79 lakh, driven by higher income from operations outpacing the increase in material and employee costs. Consolidated PBT also saw a robust 21% YoY increase to ₹257.17 lakh.

Financial Performance Highlights

The following table outlines the key financial metrics for the quarter ended June 30, 2026, compared to the same period last year:

What the Numbers Show

A notable divergence exists between the standalone and consolidated profit growth rates. While standalone net profit surged 54%, consolidated net profit attributable to equity shareholders grew by only 14%. This suggests that the subsidiaries, Opal Pharmaceuticals Pty Ltd and Medicamen Life Sciences Private Limited, contributed less proportionally to the bottom-line expansion compared to the parent entity. Additionally, other income declined significantly on a standalone basis, falling to ₹86.16 lakh from ₹172.63 lakh in the previous quarter, indicating that the core operational revenue growth was the primary driver of the quarter's success rather than ancillary gains.

Board Approvals and Corporate Actions

During its meeting held on August 14, 2026, the Board of Directors approved the unaudited financial results for the quarter ended June 30, 2026. The board also approved the draft Annual Report and Cost Audit Report for FY26.

Key corporate actions include:

• Dividend Recommendation: The board recommended a final dividend of 10%, i.e., Re 1 per equity share, subject to shareholder approval at the Annual General Meeting (AGM).
• AGM Schedule: The 33rd AGM is scheduled for September 26, 2026, via video conferencing. The record date for determining voting eligibility is September 19, 2026.
• Register Closure: The register of members will remain closed from September 19 to September 25, 2026, in connection with the dividend payment.

Regulatory Compliance

The board took note of communications from BSE Limited and NSE regarding non-compliance with Regulation 19(1)/19(2) of the SEBI (LODR) Regulations, 2015, concerning the constitution of the Nomination and Remuneration Committee. Fines totaling ₹1,10,920 each (including GST) were levied by both exchanges. The company confirmed that these payments were made on June 2, 2026, and directed management to ensure strict adherence to future compliance requirements.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE646B01010/394fd839-326d-49be-be79-616d618b1711.pdf